Item 2. Properties
ITEM 2. Properties.
The Company owns a 31,700 square foot facility that houses its primary corporate office, sales and marketing, research and development, human resources, and regulatory and quality offices. The Company also owns a 48,000 square foot facility and a 33,500 square foot facility which are used for manufacturing activities. The Company also leases a 139,000 square foot manufacturing facility. Each of these facilities is located in Bethlehem, Pennsylvania. The Company's subsidiary, DNAG, also leases a 36,000 square foot facility in Ottawa, Canada, which is used as its primary corporate office and houses sales and marketing, manufacturing, distribution, research and development, and regulatory and quality operations. The Company's subsidiary, Sherlock, leases various facilities in the United Kingdom totaling approximately 37,600 square feet, as well as outside Boston, Massachusetts, totaling approximately 5,000 square feet. These facilities house Sherlock's corporate offices, production, and research and development activities. The Company's subsidiary, BioMedomics, leases a building in North Carolina totaling approximately 2,000 square feet. The facility houses BioMedomics' corporate offices, production, and research and development activities.
The Company believes that the facilities described above are adequate for its current requirements.
ITEM 3. Legal Proceedings.
Discussion of legal matters is incorporated by reference from Note 14, Commitments and Contingencies, to the Consolidated Financial Statements included in this Annual Report on Form 10-K.
Table of Contents
ITEM 4. Mine Safety Disclosures.
Not Applicable.
Table of Contents
PART II
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.